Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.
Fernández-García F, Fernández-Rodríguez A, Fustero-Torre C, Piñeiro-Yáñez E, Wang H, Lechuga CG, Callejas S, Álvarez R, López-García A, Esteban-Burgos L, Salmón M, San Román M, Guerra C, Ambrogio C, Drosten M, Santamaría D, Al-Shahrour F, Dopazo A, Barbacid M, Musteanu M. Fernández-García F, et al. Among authors: drosten m. Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2402913121. doi: 10.1073/pnas.2402913121. Epub 2024 Aug 26. Proc Natl Acad Sci U S A. 2024. PMID: 39186651
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M. Sanclemente M, et al. Among authors: drosten m. Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27. Cancer Cell. 2018. PMID: 29395869 Free article.
Requirement for epithelial p38α in KRAS-driven lung tumor progression.
Vitos-Faleato J, Real SM, Gutierrez-Prat N, Villanueva A, Llonch E, Drosten M, Barbacid M, Nebreda AR. Vitos-Faleato J, et al. Among authors: drosten m. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2588-2596. doi: 10.1073/pnas.1921404117. Epub 2020 Jan 22. Proc Natl Acad Sci U S A. 2020. PMID: 31969449 Free PMC article.
Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M, Barbacid M. Drosten M, et al. Cancer Cell. 2020 Apr 13;37(4):543-550. doi: 10.1016/j.ccell.2020.03.013. Cancer Cell. 2020. PMID: 32289276 Free article. Review.
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M. Esteban-Burgos L, et al. Among authors: drosten m. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10. Proc Natl Acad Sci U S A. 2020. PMID: 32913049 Free PMC article.
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
Sanclemente M, Nieto P, Garcia-Alonso S, Fernández-García F, Esteban-Burgos L, Guerra C, Drosten M, Caleiras E, Martinez-Torrecuadrada J, Santamaría D, Musteanu M, Barbacid M. Sanclemente M, et al. Among authors: drosten m. Cancer Cell. 2021 Mar 8;39(3):294-296. doi: 10.1016/j.ccell.2021.01.008. Epub 2021 Jan 28. Cancer Cell. 2021. PMID: 33513349 Free article. No abstract available.
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M, Paniagua G, Lechuga CG, Fernández-García F, Zarzuela E, Álvarez-Díaz R, Musteanu M, Guerra C, Caleiras E, Muñoz J, Ortega S, Drosten M, Barbacid M. Salmón M, et al. Among authors: drosten m. Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):e2023112118. doi: 10.1073/pnas.2023112118. Proc Natl Acad Sci U S A. 2021. PMID: 34301865 Free PMC article.
46 results